These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 16770110)

  • 61. A weekly schedule of docetaxel for metastatic hormone-refractory prostate cancer.
    Ferrero JM; Foa C; Thezenas S; Ronchin P; Peyrade F; Valenza B; Lesbats G; Garnier G; Boublil JL; Tchiknavorian X; Chevallier D; Amiel J
    Oncology; 2004; 66(4):281-7. PubMed ID: 15218295
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Phase II trial evaluating a docetaxel-capecitabine combination as treatment for hormone-refractory prostate cancer.
    Ferrero JM; Chamorey E; Oudard S; Dides S; Lesbats G; Cavaglione G; Nouyrigat P; Foa C; Kaphan R
    Cancer; 2006 Aug; 107(4):738-45. PubMed ID: 16826591
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Low-dose cisplatin and UFT for hormone refractory prostate cancer].
    Hoshi S; Ohyama C; Namiki S; Hagisawa S; Satoh M; Saito S; Ono K; Shirasaka T; Arai Y
    Gan To Kagaku Ryoho; 2002 Oct; 29(10):1773-8. PubMed ID: 12402428
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Does small-cell phenotype predict the natural history of prostate cancer? A case study in disease behavior.
    Slovin SF
    Nat Clin Pract Oncol; 2007 Sep; 4(9):551-4. PubMed ID: 17728713
    [TBL] [Abstract][Full Text] [Related]  

  • 65. High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancer.
    Fizazi K; Sikes CR; Kim J; Yang J; Martinez LA; Olive MC; Logothetis CJ; Navone NM
    Anticancer Res; 2004; 24(5A):2897-903. PubMed ID: 15517894
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Characterization of prognostic factors and efficacy in a phase-II study with docetaxel and estramustine for advanced hormone refractory prostate cancer.
    Nelius T; Reiher F; Lindenmeir T; Klatte T; Rau O; Burandt J; Filleur S; Allhoff EP
    Onkologie; 2005 Nov; 28(11):573-8. PubMed ID: 16249643
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A Phase II Study of AT-101 to Overcome Bcl-2--Mediated Resistance to Androgen Deprivation Therapy in Patients With Newly Diagnosed Castration-Sensitive Metastatic Prostate Cancer.
    Stein MN; Hussain M; Stadler WM; Liu G; Tereshchenko IV; Goodin S; Jeyamohan C; Kaufman HL; Mehnert J; DiPaola RS
    Clin Genitourin Cancer; 2016 Feb; 14(1):22-7. PubMed ID: 26476589
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Docetaxel, low-dose estramustine, and doxifluridine in hormone-refractory metastatic prostate cancer.
    Wada Y; Kikuchi K; Takahashi W; Honda J; Nakanishi J; Matsumoto K; Kuwahara T; Kai N; Kikukawa H; Ueda S
    Cancer Chemother Pharmacol; 2008 Jan; 61(1):53-61. PubMed ID: 17375305
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Effect of docetaxel chemotherapy on the activity of a gonadotropin releasing hormone vaccine in patients with advanced prostate cancer.
    Triozzi PL; Bolger GB; Neidhart J; Rinehart JJ; Saleh M; Allen KO; Sellers S; Waddell MJ
    Prostate; 2005 Dec; 65(4):316-21. PubMed ID: 16015596
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Therapeutic options for hormone-refractory prostate cancer in 2007.
    Hadaschik BA; Gleave ME
    Urol Oncol; 2007; 25(5):413-9. PubMed ID: 17826663
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Evaluation of docetaxel plus estramustine in the treatment of patients with hormone-refractory prostate cancer.
    Matsumoto A; Inoue A; Yokoi S; Nozumi K; Miyazaki K; Hosoki S; Nagata M; Yamaguchi K
    Int J Urol; 2009 Aug; 16(8):687-91. PubMed ID: 19602005
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Progression after docetaxel-based chemotherapy in androgen-independent prostate cancer.
    Sella A; Sternberg C; Kovel S; Yarom N; Skoneczna I
    BJU Int; 2007 Sep; 100(3):533-5. PubMed ID: 17559560
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Actual benefit of chemo-hormonal therapy in non-castrate metastatic prostate cancer.
    Şendur MA; Akıncı MB; Ozdemir NY; Aksoy S; Dede DS; Ulas A; Zengin N; Yalçın B
    Future Oncol; 2015; 11(8):1141-3. PubMed ID: 25832870
    [No Abstract]   [Full Text] [Related]  

  • 74. Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity.
    Domingo-Domenech J; Oliva C; Rovira A; Codony-Servat J; Bosch M; Filella X; Montagut C; Tapia M; Campás C; Dang L; Rolfe M; Ross JS; Gascon P; Albanell J; Mellado B
    Clin Cancer Res; 2006 Sep; 12(18):5578-86. PubMed ID: 17000695
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Editorial comment on: Weekly docetaxel and prednisolone versus prednisolone alone in androgen-independent prostate cancer: a randomized phase II study.
    Bracarda S
    Eur Urol; 2007 Dec; 52(6):1698-9. PubMed ID: 17306444
    [No Abstract]   [Full Text] [Related]  

  • 76. The changing pattern of management for hormone-refractory, metastatic prostate cancer.
    James ND; Bloomfield D; Luscombe C
    Prostate Cancer Prostatic Dis; 2006; 9(3):221-9. PubMed ID: 16801939
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Chemotherapy of hormone-resistent cancer of the prostate].
    Matveev BP; Bukharkin BV; Kalinin SA
    Urologiia; 2005; (4):20-3. PubMed ID: 16158740
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Rapid testosterone cycling and chemotherapy for prostate cancer: a way forward or return to the past?
    Smith MR
    J Clin Oncol; 2008 Jun; 26(18):2932-3. PubMed ID: 18565878
    [No Abstract]   [Full Text] [Related]  

  • 79. [A case of hormone-refractory prostate cancer responsive to low-dose prednisolone therapy].
    Enomoto Y; Fukuhara H; Kurimoto S; Sugimoto M; Kimura A; Hosaka Y; Kitamura T
    Nihon Hinyokika Gakkai Zasshi; 1997 Jun; 88(6):636-9. PubMed ID: 9234622
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Interdisciplinary recommendations concerning the therapy for hormone-refractory prostatic carcinoma].
    Miller K; Becker K; Finke F; Geiges G; Göckel-Beining B; Hossfeld DK; Miller K; Osieka R; Rüssel C; Tesch H; Weissbach L; Wirth M; Wolff JM
    Aktuelle Urol; 2006 May; 37(3):201-4. PubMed ID: 16733822
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.